Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Δ51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene

• Published in: Blood Vol. 110; no. 7; pp. 2342 - 2350
• Main Authors: Goel, Apollina, Carlson, Stephanie K., Classic, Kelly L., Greiner, Suzanne, Naik, Shruthi, Power, Anthony T., Bell, John C., Russell, Stephen J.
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 01.10.2007; The Americain Society of Hematology; American Society of Hematology
• Series: Gene Therapy
• Subjects: Animals; Biological and medical sciences; Cell Line, Tumor; Gene Therapy; Genetic Therapy; Hematologic and hematopoietic diseases; Humans; Immunocompetence - immunology; Immunodeficiencies. Immunoglobulinopathies; Immunoglobulinopathies; Immunopathology; Iodine Radioisotopes - therapeutic use; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; Mice; Multiple Myeloma - metabolism; Multiple Myeloma - pathology; Multiple Myeloma - therapy; Multiple Myeloma - virology; Neoplasm Transplantation; Recombinant Proteins - genetics; Recombinant Proteins - metabolism; Survival Rate; Symporters - genetics; Symporters - metabolism; Vesicular stomatitis Indiana virus - genetics; Vesicular stomatitis Indiana virus - immunology; Virus Replication; Immunopathology; Hematology; Malignant hemopathy; Myeloma; Virus; Vesicular stomatitis virus; Mononegavirales; Vesiculovirus; Immunoglobulinopathy; Gene; Rhabdoviridae; Lymphoproliferative syndrome; Genetics; Medical imagery; Sodium iodide symporter; Carrier protein; Cancer
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2007-01-065573

Multiple myeloma is a radiosensitive malignancy that is currently incurable. Here, we generated a novel recombinant vesicular stomatitis virus [VSV(Δ51)-NIS] that has a deletion of methionine 51 in the matrix protein and expresses the human sodium iodide symporter (NIS) gene. VSV(Δ51)-NIS showed specific oncolytic activity against myeloma cell lines and primary myeloma cells and was able to replicate to high titers in myeloma cells in vitro. Iodide uptake assays showed accumulation of radioactive iodide in VSV(Δ51)-NIS–infected myeloma cells that was specific to the function of the NIS transgene. In bg/nd/xid mice with established subcutaneous myeloma tumors, administration of VSV(Δ51)-NIS resulted in high intratumoral virus replication and tumor regression. VSV-associated neurotoxicity was not observed. Intratumoral spread of the infection was monitored noninvasively by serial gamma camera imaging of 123I-iodide biodistribution. Dosimetry calculations based on these images pointed to the feasibility of combination radiovirotherapy with VSV(Δ51)-NIS plus 131I. Immunocompetent mice with syngeneic 5TGM1 myeloma tumors (either subcutaneous or orthotopic) showed significant enhancements of tumor regression and survival when VSV(Δ51)-NIS was combined with 131I. These results show that VSV(Δ51)-NIS is a safe oncolytic agent with significant therapeutic potential in multiple myeloma.